52 results about "Myocardial perfusion imaging" patented technology

A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.

An 82Sr / 82Rb generator column is made using a fluid impervious cylindrical container having a cover for closing the container in a fluid tight seal, and further having an inlet for connection of a conduit for delivering a fluid into the container and an outlet for connection of a conduit for conducting the fluid from the container. An ion exchange material fills the container, the ion exchange material being compacted within the container to a density that permits, the ion exchange material to be eluted at a rate of at least 5 ml / min at a fluid pressure of 1.5 pounds per square inch (10 kPa). The generator column can be repeatedly recharged with 82Sr. The generator column is compatible with either three-dimensional or two-dimensional positron emission tomography systems.

The invention discloses a pyridazinone compound marked by fluorine-18 with a molecular formula of FFPnOP and a preparation method and applications; in the formula, n is equal to 1, 2 or 3. By technical synthesis to ligand OTs-PnOP, the pyridazinone compound FFPnOP marked by radioactive fluorine-18 and stable reference compound FFPnOP are obtained by synthesis, wherein the stable reference compound is used for confirming the structure of the compound with radioactive marks; the compound has high radiochemical purity, good biological properties, high initial uptake value, simple preparation and low use cost, and is applied in the technical fields of radioactive drug chemistry and clinical nuclear medicine as a novel myocardial perfusion imaging agent marked by fluorine-18.

This invention is directed to myocardial imaging of human patients having a history of asthma or bronchospasm. In particular, the present invention uses binodenoson as a pharmacological stressor in conjunction with any one of several noninvasive and invasive diagnostic procedures available. For example, intravenous administration may be used in conjunction with a radiopharmaceutical agent and myocardial perfusion imaging to assess the severity of myocardial ischemia.

This invention relates to methods for multidetector computed tomography myocardial perfusion imaging comprising administering doses of a rate-control agent and one or more adenosine A2A receptor agonists to a mammal.

In some embodiments, the present application discloses systems and methods for cardiac MRI that allow for continuous un-interrupted acquisition without any ECG / cardiac gating or synchronization that achieves the required image contrast for imaging perfusion defects. The invention also teaches an accelerated image reconstruction technique that is tailored to the data acquisition scheme and minimizes or eliminates dark-rim image artifacts. The invention further enables concurrent imaging of perfusion and myocardial wall motion (cardiac function), which can eliminate the need for separate assessment of cardiac function (hence shortening exam time), and / or provide complementary diagnostic information in CAD patients.

The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A2A adenosine receptor agonist to a human.

The present invention provides a method for using the partial adenosine A2A receptor agonists having the following structurein myocardiological perfusion imaging.

The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.

The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.

A computed tomography system has a support stage constructed and arranged to support a subject while under observation, an x-ray illumination system arranged proximate the support stage to illuminate the subject with x-rays, an x-ray detection system arranged proximate the support stage to detect x-rays after they pass through the subject and to provide signals based on the detected x-rays, and a data processing system in communication with the x-ray detection system to receive the signals from the x-ray detection system. The computed tomography system has a dynamic mode of operation and a scanning mode of operation. The data processing system extracts information concerning a dynamic process of the subject based on signals from both the dynamic mode and the scanning mode of operation.

A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.

A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin.

An apparatus (130) and a method for adjusting, in perfusion imaging system, a periodic contrast agent injection rate signal (IS) for an injector (135) as function of an image sampling rate determined by the rotational speed of an X-ray source (107)-detector (109) assembly of an X-ray imager (100). Frequency, periodicity and pulse width of the contrast agent injection rate signal (IS) is adjusted to mitigate temporal signal aliasing in a sample of a time attenuation contrast (TAC) signal.

The invention discloses an in-vitro myocardial perfusion device which comprises a base and a support. A water bath cylinder is fixed to the top of the support, a K-H liquid bottle and a mixed gas bottle are arranged in the water bath cylinder, charging ports are formed in the top of the K-H liquid bottle and the top of the mixed gas bottle, the bottom of the K-H liquid bottle and the bottom of themixed gas bottle are connected with a spiral mixer through organic glass tubes, the spiral mixer is connected with a peristaltic pump through a glass tube, the bottom of the peristaltic pump is connected with a perfusion liquid cannula, an oblique tube is connected to the glass tube between the peristaltic pump and the perfusion liquid cannula and is connected with a 20 ml injector, a stop screwis arranged on the 20 ml injector, a 20 G liquid dropping head is arranged at the bottom of the perfusion liquid cannula, a perfusion utensil is arranged at the bottom of the 20 G liquid dropping headand is connected with a 100 ml injector through a rubber hose, the 100 ml injector is installed at the left end of the support, and a transducer is arranged on the left side of the base and is connected with the rubber hose through a glass tube.

A method for dynamically visualizing coronary information and an apparatus adapted to implement such method is described. In a preferred embodiment of the method, first dynamic cardiac data is acquired during a first cardiac stage and second dynamic cardiac data is acquired during a second cardiac stage. Then, the two data sets are visualized continuously the in a superimposed presentation, wherein the first cardiac data and the second cardiac data corresponding to a same phase within the cardiac cycle are visualized simultaneously. In this way for example information about the vessel geometry may be immediately linked with information about the muscle irrigation or perfusion. Furthermore, this useful information may be displayed in a high-contrasted and low-noise presentation.

The invention provides a 99mTc(III) complex containing arylboronic acid. A molecular formula of the 99mTc(III) complex is 99mTcC1(CDO)(CDOH)2B(F-R), wherein F is furyl and R is methoxyl, formaldehyde or hydroxymethyl. The compound has the characteristics of simple preparation, low price, high labeling rate, high radiochemical purity, high target to non-target ratio, high heart uptake value, long residence time and the like, and can be used as a novel technetium-99m labeled myocardial perfusion imaging agent which is applied to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicines.

A method for imaging a subject includes injecting the subject with a single dose of a radionuclide and acquiring, with a molecular breast imaging (MBI) system, a first set of medical image data of a breast of the subject after injection of the single dose of a radionuclide. The method also includes acquiring, with a myocardial perfusion imaging (MPI) system, a second set of medical image data of a portion of a cardiovascular system of the subject after the single dose of a radionuclide and reconstructing the first set of medical image data into a medical image of the breast of the subject and reconstructing the second set of medical image data into a medical image of the portion of the cardiovascular system of the subject.

The invention relates to a [<18>F]-fluoromethyl triphenylphosphine salt, a preparation method and application thereof, and effectively solves the problem of low ratio of myocardial uptake and non-target organs in existing myocardial perfusion imaging agents. The method includes: dissolving silver p-toluenesulfonate in acetonitrile, adding diiodomethane under stirring, conducting heating reflux, performing cooling to room temperature, filtering out light yellow solids, removing the solvent by spinning, and eluting and purifying the residue to obtain bis(p-toluenesulfonyl)-methane; under nitrogen protection, adding a [<18>F] fluoride solution into a K2.2.2 solution and a K2CO3 solution, performing drying, adding acetonitrile, conducting drying again, adding bis(p-toluenesulfonyl)methane and anhydrous acetonitrile into the dried substance, carrying out reaction, and performing cooling to room temperature, conducting column chromatography, adding an acetonitrile solution containing triphenyl phosphine to carry out reaction, and then performing cooling, filtering, column purification, solvent removal, normal saline dissolution and filtering, thus obtaining the [<18>F]-fluoromethyl triphenylphosphine salt. The [<18>F]-fluoromethyl triphenylphosphine salt provided by the invention has the characteristics of high cardiac and myocardial uptake, fast clearance rate in main organs, and high heart blood ratio, heart-lung ratio and heart-liver ratio, low cost, and can acquire clear heart Micro-PET images.

This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with 64Cu or 18F. Also provided are methods for synthesizing the compounds, methods for derivatizing the compounds, and derivatives thereof.

This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with 64Cu or 18F. Also provided are methods for synthesizing the compounds, methods for derivatizing the compounds, and derivatives thereof.

The invention relates to a survival myocardial evaluation method, which is used for evaluating based on gating SPECT myocardial perfusion development myocardial functions in combination with myocardial perfusion, and comprises the following steps: firstly, acquiring an examination image by adopting gating SPECT myocardial perfusion development, and reconstructing to obtain a left ventricular minoraxis image, a left ventricular horizontal major axis image and a left ventricular vertical major axis image; then carrying out semi-quantitative scoring on blood perfusion uptake of the left ventricular myocardial segment, and judging a perfusion reduction segment; quantitatively evaluating to obtain the blood perfusion uptake ratio of each segment of the left ventricular myocardium; analyzing the reconstructed gated SPECT myocardial perfusion imaging, respectively obtaining a ventricular wall movement score and a thickening rate score of each myocardial segment, and finally substituting theparameters into an evaluation model for calculation. Evaluation is carried out based on gated SPECT myocardial perfusion imaging myocardial functions in combination with myocardial perfusion, and themethod is particularly suitable for evaluating survival myocardium of coronary heart disease heart failure patients before blood supply reconstruction and guiding clinical treatment decisions.

The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents.

The present disclosure is directed to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a compound linked to an imaging moiety, wherein said compound binds MC-1, and scanning the patient using diagnostic imaging. The invention also relates to kits comprising said compound or precursor compounds linked or not linked to an imaging moiety.